Valganciclovir ( DrugBank: Valganciclovir )

4 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
85	特発性間質性肺炎	2
97	潰瘍性大腸炎	2
299	嚢胞性線維症	1
331	特発性多中心性キャッスルマン病	3

85. 特発性間質性肺炎

臨床試験数 : 627 / 薬物数 : 443 - (DrugBank : 120) / 標的遺伝子数 : 99 - 標的パスウェイ数 : 212

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05041426 (ClinicalTrials.gov)	December 6, 2021	20/4/2021	Letermovir for CMV Prevention After Lung Transplantation	An Open-label Pilot Protocol to Evaluate the Efficacy of Letermovir for the Prevention of Human Cyto ...	Lung Transplant;CMV	Drug: Letermovir;Drug: Valganciclovir	Fernanda P Silveira, MD, MS	Merck Sharp & Dohme LLC	Recruiting	18 Years	100 Years	All	30	Phase 2	United States
2	NCT02871401 (ClinicalTrials.gov)	January 3, 2018	15/8/2016	A Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF)	A Phase One-B (1B) Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF)	Idiopathic Pulmonary Fibrosis	Drug: Valganciclovir;Drug: Placebo	Vanderbilt University Medical Center	Genentech, Inc.	Completed	21 Years	80 Years	All	31	Phase 1	United States

First Previous1Next Last

97. 潰瘍性大腸炎

臨床試験数 : 2,630 / 薬物数 : 1,459 - (DrugBank : 265) / 標的遺伝子数 : 144 - 標的パスウェイ数 : 202

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04064697 (ClinicalTrials.gov)	April 22, 2021	20/8/2019	Impact of Anti-cytomegalovirus Treatment in the Management of Relapsing Ulcerative Colitis Requiring ...	Impact of Anti-cytomegalovirus (Valganciclovir) Treatment in the Management of Relapsing Ulcerative ...	Ulcerative Colitis, Unspecified	Drug: Valganciclovir	Centre Hospitalier Universitaire de Saint Etienne	Ministry of Health, France	Recruiting	18 Years	N/A	All	120	Phase 3	France
2	EUCTR2019-001032-54-FR (EUCTR)	23/07/2019	19/06/2019	Impact of anti-cytomegalovirus (valganciclovir) treatment in the management of relapsing ulcerative ...	Impact of anti-cytomegalovirus (valganciclovir) treatment in the management of relapsing ulcerative ...	Patient with active ulcerative colitis who failed to anti-TNF with endoscopic active disease with an ...	Trade Name: valganciclovir Product Name: valganciclovir Trade Name: vedolizumab Product Name: vedolizum ...	CHU de Saint Etienne	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	120	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (P ...	France

First Previous1Next Last

299. 嚢胞性線維症

臨床試験数 : 1,695 / 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00377741 (ClinicalTrials.gov)	December 2004	15/9/2006	A Relative Bioavailability Study of Valcyte (Valganciclovir) in Lung Transplant Recipients With or W ...	Relative Bioavailability Study of Ganciclovir From the Pro-drug, Valganciclovir, in Lung Transplant ...	Cytomegalovirus Infections	Drug: valganciclovir [Valcyte]	Hoffmann-La Roche	NULL	Completed	14 Years	N/A	All	31	Phase 1	United States

First Previous1Next Last

331. 特発性多中心性キャッスルマン病

臨床試験数 : 33 / 薬物数 : 41 - (DrugBank : 21) / 標的遺伝子数 : 22 - 標的パスウェイ数 : 123

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01441063 (ClinicalTrials.gov)	September 13, 2011	24/9/2011	Tocilizumab for KSHV-Associated Multicentric Castleman Disease	Pilot Study of Tocilizumab in Patients With Symptomatic Kaposi Sarcoma Herpesvirus (KSHV) - Associat ...	Castleman Disease;Multicentric Castleman Disease;Giant Lymph Node Hyperplasia	Drug: Zidovudine;Drug: Tocilizumab;Drug: Valganciclovir (VGC)	National Cancer Institute (NCI)	NULL	Completed	18 Years	N/A	All	8	Phase 2	United States
2	NCT00361933 (ClinicalTrials.gov)	December 2008	8/8/2006	Valganciclovir to Treat HHV-8 Associated Multicentric Castleman's Disease	Clinical and Virologic Response to HHV-8 Associated Multicentric Castleman's Disease to Valganciclov ...	Giant Lymph Node Hyperplasia	Drug: Valganciclovir	University of Washington	Hoffmann-La Roche	Withdrawn	18 Years	N/A	All	0	Phase 4	United States
3	NCT00092222 (ClinicalTrials.gov)	October 28, 2004	21/9/2004	Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Corr ...	Targeted Oncolytic Virotherapy and Natural History Study of KSHV-Associated Multicentric Castleman's ...	Lymphoproliferative Disorder;HHV-8;Malignancy;HIV	Drug: Etoposide;Drug: Interferon-alpha;Drug: Rituximab;Drug: Zidovudine;Drug: Liposomal Doxorubicin; ...	National Cancer Institute (NCI)	NULL	Active, not recruiting	18 Years	N/A	All	75	Phase 2	United States

First Previous1Next Last

先頭へ